Shanghai – August 27, 2026 – Cooley advised AusperBio, a near-commercial biopharmaceutical company focused on developing targeted oligonucleotide therapeutics for the treatment of chronic hepatitis B (CHB) and other diseases, on the closing of its $120 million Series C financing.

The financing was led by a leading strategic investor, with participation from new investor RA Capital, alongside continued support from existing investors, including HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital, and CDH Investments. 

The financing will support the continued development of AHB-137, AusperBio's lead investigational ASO therapy for CHB, including its Phase 3 registrational program and commercialization readiness. Proceeds will also accelerate the development of AHB-171, the Company's investigational HBV siRNA candidate built on its proprietary Au-HALO™ targeted delivery platform, advance next-generation combination approaches for CHB, and further expand the Company's pipeline of targeted oligonucleotide therapeutics addressing significant unmet medical needs.

Lawyers Andrew Harline and Lunga Su led the Cooley team advising AusperBio.

Cooley previously advised AusperBio on its $63 million Series B2 financing in September 2025, $50 million Series B+ financing in May 2025, $73 million Series B financing in December 2024 and $37 million Series A in July 2024.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation.

Cooley has nearly 1,400 lawyers across 19 offices in the United States, Asia and Europe, and a total workforce of more than 3,000 people.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.